Fresh From the Bench: Latest Federal Circuit Court Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Best Medical International, Inc. v. Elekta Inc., Appeal Nos. 2021-2099, -2100 (Fed. Cir. Aug. 26, 2022)
In this week’s Case of the Week, the Federal Circuit addressed issues of jurisdiction where a challenged claim was canceled through ex parte reexamination during pending inter partes review proceedings, and otherwise affirmed the Patent Trial and Appeal Board’s determination that challenged claims were obvious over the prior art. The Court’s decision turned in part on an analysis of the level of skill in the art that is appropriate for an obviousness analysis.
Read more.
By Annie White
ALSO THIS WEEK
n Re: Jeffrey A. Killian, Appeal No. 2021-2113 (Fed. Cir. Aug. 23, 2022)
In this case, the Federal Circuit affirmed a patent examiner’s rejection of application claims as patent-ineligible under 35 U.S.C. § 101. The claims were directed to a method of determining eligibility for Social Security benefits using a computer to compare information from state and federal databases, and the Court agreed that they were directed to generalized and conventional steps performed with a computer and were ineligible for patenting under the Alice/Mayo analysis. On appeal, the applicant launched “myriad” arguments “directed not to the specifics of [his] application to the corpus of § 101 jurisprudence.” The Court gamely addressed and rejected arguments that the Supreme Court’s standards promulgated in Alice and Mayo were vague, ambiguous, and ran afoul of the Administrative Procedures Act and the Fifth Amendment Due Process Clause in various particulars of application. The Court defended the standards and collected examples of guidance provided in its precedent, but also concluded it was bound to apply them in any event until they were overturned by the Supreme Court. The Patent Trial and Appeal Board’s decision affirming the rejections was affirmed.
The opinion can be found here.
Edited by Nika Aldrich and Scott D. Eads, Schwabe, Williamson & Wyatt
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…